US EditionSlipstream Study Sheds Light on High Healthcare Costs and Unmet Needs in Rare Bleeding Disorder
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Slipstream Study Sheds Light on High Healthcare Costs and Unmet Needs in Rare Bleeding Disorder
BLUE BELL, PA — Slipstream has co-authored a landmark study on Hereditary Hemorrhagic Telangiectasia (HHT), offering the most comprehensive analysis to date of the economic and clinical burden of this rare genetic bleeding disorder. The study, recently published in the American Journal of Hematology, represents the largest examination of HHT patients ever conducted, analyzing data from more than 24,000 individuals across the U.S. Drawing on Komo…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
